Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Curr Breast Cancer Rep. 2015 Oct 10;7(4):210–214. doi: 10.1007/s12609-015-0197-9

Table 1.

Ongoing clinical trials with PI3K inhibitors in HER2+ breast cancer

Trial type Type of PI3K inhibitor Clinical trial name Identifier
Phase I/II α-Specific PI3K inhibitor BYL719+ T-DM1 in HER2(+) metastatic breast cancer pts who progress on prior trastuzumab and taxane treatment NCT02038010
Dual PI3K/mTOR inhibitor A phase Ib/II study of BEZ235 and trastuzumab in patients with HER2-positive breast cancer who failed prior to trastuzumab NCT01471847
Pan-PI3K inhibitor Study of XL147 (SAR245408) in combination with trastuzumab or paclitaxel and trastuzumab in subjects with metastatic breast cancer who have progressed on a previous trastuzumab-based regimen NCT01042925
Safety and efficacy of BKM120 and lapatinib in HER2+/PI3K-activated, trastuzumab-resistant advanced breast cancer (PIKHER2) NCT01589861
Phase II NeoPHOEBE: Neoadjuvant trastuzumab+BKM120 in combination with weekly paclitaxel in HER2-positive primary breast cancer NCT01816594